Dnaprint Genomics Stock Working Capital
DNAPrint Genomics fundamentals help investors to digest information that contributes to DNAPrint Genomics' financial success or failures. It also enables traders to predict the movement of DNAPrint Stock. The fundamental analysis module provides a way to measure DNAPrint Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DNAPrint Genomics stock.
DNAPrint |
DNAPrint Genomics Company Working Capital Analysis
DNAPrint Genomics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current DNAPrint Genomics Working Capital | (9.35 M) |
Most of DNAPrint Genomics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DNAPrint Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAccording to the company's disclosures, DNAPrint Genomics has a Working Capital of (9.35 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The working capital for all United States stocks is notably higher than that of the company.
DNAPrint Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNAPrint Genomics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNAPrint Genomics could also be used in its relative valuation, which is a method of valuing DNAPrint Genomics by comparing valuation metrics of similar companies.DNAPrint Genomics is currently under evaluation in working capital category among its peers.
DNAPrint Fundamentals
| Return On Asset | -1.05 | |||
| Profit Margin | (2.36) % | |||
| Operating Margin | (7.31) % | |||
| Current Valuation | 5.21 M | |||
| Shares Outstanding | 644.61 M | |||
| Shares Owned By Institutions | 0.18 % | |||
| Price To Sales | 0.0003 X | |||
| Revenue | 2.43 M | |||
| Gross Profit | 754.07 K | |||
| EBITDA | (5.78 M) | |||
| Net Income | (12.35 M) | |||
| Cash And Equivalents | 134.35 K | |||
| Total Debt | 240 K | |||
| Current Ratio | 0.17 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (5.78 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 24 | |||
| Beta | 23.48 | |||
| Market Capitalization | 644 | |||
| Total Asset | 10.27 M | |||
| Retained Earnings | (45.53 M) | |||
| Working Capital | (9.35 M) | |||
| Current Asset | 1.89 M | |||
| Current Liabilities | 11.24 M | |||
| Net Asset | 10.27 M |
About DNAPrint Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DNAPrint Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DNAPrint Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DNAPrint Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in DNAPrint Stock
If you are still planning to invest in DNAPrint Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DNAPrint Genomics' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |